The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Giftify (GIFT) announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Eli Lilly's pipeline holds substantial promise, particularly with the FDA’s approval of Zepbound for Obstructive ... with a market cap of $793 billion. A discounted cash flow (DCF) analysis ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue ... The cost of equity, which is used as the discount rate, is based on the 10-Year Treasury ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought ... for an ...

Even now, with the dip in value, its price-to-earnings (P/E) multiple is close to 80, which still isn't terribly cheap ... Eli Lilly still has a couple of fantastic drugs in Mounjaro and Zepbound ...